A Potent Immunotherapy for Solid Tumor Cancers

New immunotherapies for the treatment of melanoma, osteosarcoma, pancreatic cancer, and other solid tumor cancers

Background & Overview

Immunotherapy is becoming one of the most popular new area of research for treating different types of cancers. By using antibodies to help target cancers and deliver cancer-killing drugs to the tumors, immunotherapies have shown early promise. However, there is still a large number of patients that either do not respond to treatment or become hypersensitive to immunotherapy. For example, in the case of melanoma, only 20-40% of patients respond to immunotherapy.

The intravenous administration of the novel technology can effectively modulate the immune system which may result in a striking regression of advanced solid tumor cancers. Patients that may have failed SOC immunotherapy could benefit from the subject technology. Due to combination of potency and efficacy, the subject technology has high potential to induce an antitumor response that other SOC treatments have failed.

Novel immunotherapy that activates the immune system through the deactivation of Mac-1 of tumor-associated macrophages to improve antigen presenting capability and assist in T-cell activation.

Value Proposition

The subject technology has been tested at multiple dosages and the biodistribution has been studied. Small animal studies and in vitro assays using human monocytes have been conducted.

Opportunity

We seek commercialization partners with a commitment to and leadership position in global health issues. Opportunities for collaboration may take a variety of forms, including direct licensing or in conjunction with a private equity investor in a startup to develop and commercialize the technology; sponsored research.

Technology Readiness
Small animal studies and toxicity tests completed

Commercial Pathway
Available for licensing or start-up consideration

Intellectual Property
Two patent filings

Inventors: Mei Zhang PhD, Alex Huang, MD PhD
Licensing Contact: Wayne Hawthorne
Sr. Licensing Officer | (216) 368-6104 | wayne.hawthorne@case.edu